Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA [Yahoo! Finance]
Achieve Life Sciences, Inc. - Common Shares (ACHV)
Last achieve life sciences, inc. - common shares earnings: 3/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.achievelifesciences.com
Company Research
Source: Yahoo! Finance
The FDA agreed on the proposed single Phase 3 study design and additional requirements for submitting a supplemental new drug application. The Phase 3 ORCA-V2 trial will assess the efficacy and safety of cytisinicline in approximately 800 adults who use e-cigarettes or nicotine vapes and do not currently smoke cigarettes. The trial is expected to initiate in the third quarter of 2025. Cytisinicline has been granted Breakthrough Therapy designation to address the critical need for a treatment for nicotine e-cigarette cessation, with no FDA-approved treatments currently available. Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping Cessation SEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, announced today the successful outcome of its End-of-Phase
Show less
Read more
Impact Snapshot
Event Time:
ACHV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACHV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACHV alerts
High impacting Achieve Life Sciences, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ACHV
News
- Achieve Life Sciences Appoints Mark Oki as Chief Financial OfficerGlobeNewswire
- Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDAGlobeNewswire
- Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma) [Yahoo! Finance]Yahoo! Finance
- Achieve Life Sciences, Inc. (NASDAQ: ACHV) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
- Achieve Life Sciences Announces Participation at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
ACHV
Earnings
- 11/7/24 - Miss
ACHV
Sec Filings
- 12/9/24 - Form 4
- 12/9/24 - Form 4
- 12/9/24 - Form 3
- ACHV's page on the SEC website